These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 38769930)

  • 21. Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study.
    Huang J; Xu J; Chen Y; Zhuang W; Zhang Y; Chen Z; Chen J; Zhang H; Niu Z; Fan Q; Lin L; Gu K; Liu Y; Ba Y; Miao Z; Jiang X; Zeng M; Chen J; Fu Z; Gan L; Wang J; Zhan X; Liu T; Li Z; Shen L; Shu Y; Zhang T; Yang Q; Zou J;
    Lancet Oncol; 2020 Jun; 21(6):832-842. PubMed ID: 32416073
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical Efficacy of Taxol Plus Platinum (TP) Chemotherapy Combined with Delayed Administration of PD-1 Inhibitors in Patients with Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma: A Retrospective Study.
    Shen L; Chen Z; Zhang Z; Wu Y; Ren Y; Li Y; Li Y; Yin X; Han F; Chen Y
    Drug Des Devel Ther; 2024; 18():2761-2773. PubMed ID: 38979399
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical features and treatment outcomes of PD-1 inhibitor therapy in elderly patients (≥ 65 years) with advanced esophageal squamous cell carcinoma: a real-world study.
    Yu Y; Wu T; Gan W; Liu C; Zhang R; Zheng J; Xiong J; Chen J; Li J
    Clin Transl Oncol; 2024 Sep; 26(9):2360-2368. PubMed ID: 38602642
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness of Immune Checkpoint Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma: A Meta-analysis Including Low PD-L1 Subgroups.
    Yap DWT; Leone AG; Wong NZH; Zhao JJ; Tey JCS; Sundar R; Pietrantonio F
    JAMA Oncol; 2023 Feb; 9(2):215-224. PubMed ID: 36480211
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PD-1 inhibitors plus chemotherapy as first-line therapy for stage IV ESCC.
    Lu J; Qin Z; Ma J; Yao N; Qu W; Cui L; Yuan S; Yao Y
    J Chemother; 2024 May; 36(3):258-263. PubMed ID: 37592822
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma.
    Zhang B; Qi L; Wang X; Xu J; Liu Y; Mu L; Wang X; Bai L; Huang J
    Cancer Commun (Lond); 2020 Dec; 40(12):711-720. PubMed ID: 33314747
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PD-1 inhibitors combined with paclitaxel and cisplatin in first-line treatment of esophageal squamous cell carcinoma (ESCC): a network meta-analysis.
    Zhao J; Zhang S; Guo X; Li C; Yang B; Qu X; Wang S
    BMC Cancer; 2023 Dec; 23(1):1221. PubMed ID: 38082441
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PD-1/PD-L1 based immunochemotherapy versus chemotherapy alone for advanced esophageal squamous cell carcinoma: A meta-analysis focus on PD-L1 expression level.
    Jin Z; Wang J; Sun J; Zhu C; Zhang J; Zhang B
    Cancer Rep (Hoboken); 2023 Jul; 6(7):e1794. PubMed ID: 37199321
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial.
    Wang ZX; Cui C; Yao J; Zhang Y; Li M; Feng J; Yang S; Fan Y; Shi J; Zhang X; Shen L; Shu Y; Wang C; Dai T; Mao T; Chen L; Guo Z; Liu B; Pan H; Cang S; Jiang Y; Wang J; Ye M; Chen Z; Jiang D; Lin Q; Ren W; Wang J; Wu L; Xu Y; Miao Z; Sun M; Xie C; Liu Y; Wang Q; Zhao L; Li Q; Huang C; Jiang K; Yang K; Li D; Liu Y; Zhu Z; Chen R; Jia L; Li W; Liao W; Liu HX; Ma D; Ma J; Qin Y; Shi Z; Wei Q; Xiao K; Zhang Y; Zhang Y; Chen X; Dai G; He J; Li J; Li G; Liu Y; Liu Z; Yuan X; Zhang J; Fu Z; He Y; Ju F; Liu Z; Tang P; Wang T; Wang W; Zhang J; Luo X; Tang X; May R; Feng H; Yao S; Keegan P; Xu RH; Wang F
    Cancer Cell; 2022 Mar; 40(3):277-288.e3. PubMed ID: 35245446
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of Efficacy and Safety of Combined Chemoimmunotherapy With or Without Radiation Therapy for Stage IVB Esophageal Squamous Cell Carcinoma: A Multicenter Propensity Score Matching Analysis.
    Chen B; Chen W; Cheng Q; Zhang H; Wang B; Xu Y; Yang C; Cheng X; Wang R; Wang S; Cen P; Wang L; Dragomir MP; Zhu Y; Liu S; Xi M; Li Q; Chen B
    Int J Radiat Oncol Biol Phys; 2024 Nov; 120(4):1084-1095. PubMed ID: 38936631
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
    Ba H; Liu L; Peng Q; Chen J; Zhu YD
    BMC Cancer; 2021 Nov; 21(1):1220. PubMed ID: 34774004
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Second-line tislelizumab versus chemotherapy in Japanese patients with advanced or metastatic esophageal squamous cell carcinoma: subgroup analysis from RATIONALE-302.
    Hara H; Satoh T; Kojima T; Tsushima T; Sunakawa Y; Okada M; Ding N; Wu H; Li L; Yu T; Barnes G; Kato K
    Esophagus; 2024 Apr; 21(2):102-110. PubMed ID: 38240916
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness and safety of first-line immune checkpoint inhibitors for patients with extensive-stage small cell lung carcinoma: A systematic review and network meta-analysis.
    Du J; Wang X; Fan L; Shan X; Li M; Liu L
    Heliyon; 2023 Apr; 9(4):e14794. PubMed ID: 37095958
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PD-1 inhibitor combined with chemotherapy for first-line treatment of esophageal squamous cell carcinoma patients with distant metastasis: a real-world retrospective study.
    Gao L; Tang L; Peng J; Hu Z; Yang J; Liu B
    Front Immunol; 2024; 15():1353445. PubMed ID: 38576619
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy.
    Cortellini A; Di Maio M; Nigro O; Leonetti A; Cortinovis DL; Aerts JG; Guaitoli G; Barbieri F; Giusti R; Ferrara MG; Bria E; D'Argento E; Grossi F; Rijavec E; Guida A; Berardi R; Torniai M; Sforza V; Genova C; Mazzoni F; Garassino MC; De Toma A; Signorelli D; Gelibter A; Siringo M; Marchetti P; Macerelli M; Rastelli F; Chiari R; Rocco D; Della Gravara L; Inno A; Michele T; Grassadonia A; Di Marino P; Mansueto G; Zoratto F; Filetti M; Santini D; Citarella F; Russano M; Cantini L; Tuzi A; Bordi P; Minuti G; Landi L; Ricciardi S; Migliorino MR; Passiglia F; Bironzo P; Metro G; Adamo V; Russo A; Spinelli GP; Banna GL; Friedlaender A; Addeo A; Cannita K; Ficorella C; Porzio G; Pinato DJ
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33827906
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer.
    Kojima T; Shah MA; Muro K; Francois E; Adenis A; Hsu CH; Doi T; Moriwaki T; Kim SB; Lee SH; Bennouna J; Kato K; Shen L; Enzinger P; Qin SK; Ferreira P; Chen J; Girotto G; de la Fouchardiere C; Senellart H; Al-Rajabi R; Lordick F; Wang R; Suryawanshi S; Bhagia P; Kang SP; Metges JP;
    J Clin Oncol; 2020 Dec; 38(35):4138-4148. PubMed ID: 33026938
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.
    Reck M; Mok TSK; Nishio M; Jotte RM; Cappuzzo F; Orlandi F; Stroyakovskiy D; Nogami N; Rodríguez-Abreu D; Moro-Sibilot D; Thomas CA; Barlesi F; Finley G; Lee A; Coleman S; Deng Y; Kowanetz M; Shankar G; Lin W; Socinski MA;
    Lancet Respir Med; 2019 May; 7(5):387-401. PubMed ID: 30922878
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of the profiles of first-line PD-1/PD-L1 inhibitors for advanced NSCLC lacking driver gene mutations: a systematic review and Bayesian network meta-analysis.
    Wenfan F; Manman X; Xingyuan S; Zeyong J; Jian Z; Lu D
    Ther Adv Chronic Dis; 2023; 14():20406223231189224. PubMed ID: 37841212
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of PD-1/PD-L1 Inhibitors versus Chemotherapy in Lung Cancer with Brain Metastases: A Systematic Review and Meta-Analysis.
    Yang X; Zeng Y; Tan Q; Huang Z; Jia J; Jiang G
    J Immunol Res; 2022; 2022():4518898. PubMed ID: 35637793
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of first-line immunotherapy plus chemotherapy in treating patients with extensive-stage small cell lung cancer: a Bayesian network meta-analysis.
    Zhang T; Li W; Diwu D; Chen L; Chen X; Wang H
    Front Immunol; 2023; 14():1197044. PubMed ID: 37435087
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.